| Trial ID: | L6408 |
| Source ID: | NCT00943371
|
| Associated Drug: |
Mk6349
|
| Title: |
A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK6349|DRUG: Comparator: Placebo to MK6349
|
| Outcome Measures: |
Primary: Safety and tolerability of MK6349 after single and divided rising doses based on assessment of clinical and laboratory evaluations and adverse experiences, Through 30 days after the last dose of study drug|15-Hour weighted mean plasma glucose (WMG) concentration, 15 hours postdose | Secondary: 4-Hour weighted mean plasma glucose (WMG) concentration, 4 hours postdose
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
28
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-08
|
| Completion Date: |
2009-05
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-27
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00943371
|
